March 13, 2014
A Delaware magistrate judge urged the court on Thursday toss a shareholder derivative suit claiming Allergan Inc.'s directors gave investors misleading information about a proposed executive bonus plan, saying the pharmaceutical company's motion to dismiss should be granted on "demand futility" grounds.
February 09, 2012
The former president of Allergan Inc. was dismissed Thursday from a shareholder derivative suit accusing the company's board of directors of issuing a misleading statement requesting approval of a defective executive compensation plan that cost the pharmaceutical company millions in tax benefits.
November 23, 2011
Allergan Inc.'s board of directors was hit Monday with a shareholder derivative suit alleging it issued a misleading statement asking shareholders to approve a defective executive compensation plan that cost the pharmaceutical company millions in tax benefits.